Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
|
Add to portfolio |
|
|
|
| Price: |
$1.81
| | Metrics |
| OS: |
4.42
|
M
| |
-557
|
% ROE
|
| Market cap: |
$8.01
|
M
| |
-193
|
% ROIC
|
|
Net cash:
|
$18.2
|
M
| |
$4.12
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($51.0)
|
M
| |
|
|
| EPS |
($12.58)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.9 | 3.9 | 36.1 | 4.8 | 2.4 | 1.9 | 0.6 |
| Revenue growth | -100.0% | -77.6% | -89.1% | 649.5% | 97.6% | 27.7% | 194.8% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.9 | 3.9 | 36.1 | 4.8 | 2.4 | 1.9 | 0.6 |
| Gross margin | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 16.1 | 36.4 | 98.3 | 89.6 | 48.6 | 26.0 | 15.4 | 5.9 |
| General and administrative | 18.7 | 20.4 | 28.5 | 23.6 | 13.0 | 9.0 | 6.5 | 3.6 |
| EBIT | -39.8 | -56.0 | -122.8 | -77.1 | -56.7 | -32.6 | -20.0 | -8.9 |
| EBIT margin | | -6350.1% | -3119.2% | -213.3% | -1176.8% | -1334.4% | -1045.6% | -1365.5% |
| Pre-tax income | -42.3 | -45.6 | -111.3 | -71.5 | -55.7 | -32.4 | -20.0 | -8.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -42.3 | -45.6 | -111.3 | -71.5 | -55.7 | -32.4 | -20.0 | -8.9 |
| Net margin | | -5176.4% | -2826.1% | -197.7% | -1154.5% | -1328.6% | -1046.3% | -1365.1% |
| |
| Diluted EPS | ($10.15) | ($11.15) | ($1.42) | ($1.12) | ($0.98) | ($0.65) | ($0.49) | ($0.28) |
| Shares outstanding (diluted) | 4.2 | 4.1 | 78.1 | 63.9 | 57.0 | 50.2 | 41.1 | 31.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|